Home / Health / Antibodies from recovered cases, antivirals may be bridge to Covid vaccine

Antibodies from recovered cases, antivirals may be bridge to Covid vaccine

Antibody-based medications, other blood products from recovered patients and antivirals are being investigated as early treatments, Fauci said

Premium

Immunization against SARS-CoV-2 could begin in the U.S. in November or December, Fauci said. Photo: Bloomberg

4 min read Last Updated : Sep 27 2020 | 7:02 AM IST

Monoclonal antibodies that stop the coronavirus from spreading in the body are among promising strategies for averting severe illness from Covid-19 before vaccines arrive, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

Antibody-based medications, other blood products from recovered patients and antivirals are being investigated as early treatments, Fauci said. The aim is to prevent patients from developing the serious lung damage for which Gilead Sciences Inc.’s remdesivir and the anti-inflammatory drug dexamethasone are administered.

“We are focusing very heavily now on treatment of early infection and, or prevention of infection,” Fauci told the Journal of the

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in